Switch theme
Sign up to access all valuation multiples
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
2005
270
LTM Revenue $63.8M
LTM EBITDA -$341M
$392M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Syndax has a last 12-month revenue (LTM) of $63.8M and a last 12-month EBITDA of -$341M.
In the most recent fiscal year, Syndax achieved revenue of $23.7M and an EBITDA of -$314M.
Syndax expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Syndax valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $63.8M | XXX | $23.7M | XXX | XXX | XXX |
| Gross Profit | $58.9M | XXX | $22.9M | XXX | XXX | XXX |
| Gross Margin | 92% | XXX | 97% | XXX | XXX | XXX |
| EBITDA | -$341M | XXX | -$314M | XXX | XXX | XXX |
| EBITDA Margin | -534% | XXX | -1325% | XXX | XXX | XXX |
| EBIT | -$332M | XXX | -$340M | XXX | XXX | XXX |
| EBIT Margin | -521% | XXX | -1434% | XXX | XXX | XXX |
| Net Profit | -$320M | XXX | -$319M | XXX | XXX | XXX |
| Net Margin | -501% | XXX | -1346% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $190M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Syndax's stock price is $11.
Syndax has current market cap of $907M, and EV of $392M.
See Syndax trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $392M | $907M | XXX | XXX | XXX | XXX | $-3.74 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Syndax has market cap of $907M and EV of $392M.
Syndax's trades at 16.6x EV/Revenue multiple, and -1.3x EV/EBITDA.
Equity research analysts estimate Syndax's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Syndax has a P/E ratio of -2.8x.
See valuation multiples for Syndax and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $907M | XXX | $907M | XXX | XXX | XXX |
| EV (current) | $392M | XXX | $392M | XXX | XXX | XXX |
| EV/Revenue | 6.2x | XXX | 16.6x | XXX | XXX | XXX |
| EV/EBITDA | -1.2x | XXX | -1.3x | XXX | XXX | XXX |
| EV/EBIT | -1.2x | XXX | -1.2x | XXX | XXX | XXX |
| EV/Gross Profit | 6.7x | XXX | n/a | XXX | XXX | XXX |
| P/E | -2.8x | XXX | -2.8x | XXX | XXX | XXX |
| EV/FCF | -1.9x | XXX | -1.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSyndax's last 12 month revenue growth is 183%
Syndax's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $1.3M for the same period.
Syndax's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Syndax's rule of X is -76% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Syndax and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 183% | XXX | 235% | XXX | XXX | XXX |
| EBITDA Margin | -534% | XXX | -1325% | XXX | XXX | XXX |
| EBITDA Growth | -18% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | -1142% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -76% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 1020% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 1531% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Syndax acquired XXX companies to date.
Last acquisition by Syndax was XXXXXXXX, XXXXX XXXXX XXXXXX . Syndax acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Syndax founded? | Syndax was founded in 2005. |
| Where is Syndax headquartered? | Syndax is headquartered in United States of America. |
| How many employees does Syndax have? | As of today, Syndax has 270 employees. |
| Who is the CEO of Syndax? | Syndax's CEO is Mr. Michael A. Metzger. |
| Is Syndax publicy listed? | Yes, Syndax is a public company listed on NAS. |
| What is the stock symbol of Syndax? | Syndax trades under SNDX ticker. |
| When did Syndax go public? | Syndax went public in 2016. |
| Who are competitors of Syndax? | Similar companies to Syndax include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Syndax? | Syndax's current market cap is $907M |
| What is the current revenue of Syndax? | Syndax's last 12 months revenue is $63.8M. |
| What is the current revenue growth of Syndax? | Syndax revenue growth (NTM/LTM) is 183%. |
| What is the current EV/Revenue multiple of Syndax? | Current revenue multiple of Syndax is 6.2x. |
| Is Syndax profitable? | Yes, Syndax is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Syndax? | Syndax's last 12 months EBITDA is -$341M. |
| What is Syndax's EBITDA margin? | Syndax's last 12 months EBITDA margin is -534%. |
| What is the current EV/EBITDA multiple of Syndax? | Current EBITDA multiple of Syndax is -1.2x. |
| What is the current FCF of Syndax? | Syndax's last 12 months FCF is -$201M. |
| What is Syndax's FCF margin? | Syndax's last 12 months FCF margin is -316%. |
| What is the current EV/FCF multiple of Syndax? | Current FCF multiple of Syndax is -1.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
